Literature DB >> 2107494

Cross-talk in signal transduction: TPA-inducible factor jun/AP-1 activates cAMP-responsive enhancer elements.

P Sassone-Corsi1, L J Ransone, I M Verma.   

Abstract

The product of the jun proto-oncogene has been identified as one form of the transcription factor AP-1. The p55fos protein associates with jun/AP-1 by means of a heterodimer which requires intact 'leucine zipper' domains of both proteins. The fos/jun heterodimer binds to and activates transcription from TPA-responsive promoter elements (TGACTCA), which represent one final target of the protein kinase C pathway. The other main signal transduction pathway, initiated by the activation of the adenylate cyclase, involves the transcription factor CREB. The promoter element recognized by CREB, a cyclic AMP responsive element (CRE), consist of a palyndromic sequence similar to a TRE (TGACGTCA). We show that jun efficiently trans-activates CRE sequences and that fos and jun efficiently bind and cooperate in activating CRE promoter elements. The similarity between TRE and CRE sequences may involve an interplay in transcriptional regulation and 'cross-talk' between components of the two major signal transduction pathways.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2107494

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion.

Authors:  A Ray; K S LaForge; P B Sehgal
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  Global expression analysis identified a preferentially nerve growth factor-induced transcriptional program regulated by sustained mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) and AP-1 protein activation during PC12 cell differentiation.

Authors:  Steven Mullenbrock; Janki Shah; Geoffrey M Cooper
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

Review 3.  Fos-jun and the primary genomic response in the nervous system. Possible physiological role and pathophysiological significance.

Authors:  J P Doucet; S P Squinto; N G Bazan
Journal:  Mol Neurobiol       Date:  1990 Spring-Summer       Impact factor: 5.590

4.  Transcription mediated by a cAMP-responsive promoter element is reduced upon activation of dopamine D2 receptors.

Authors:  J P Montmayeur; E Borrelli
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

5.  Mechanism of cAMP regulation of renin gene transcription by proximal promoter.

Authors:  K Tamura; S Umemura; S Yamaguchi; T Iwamoto; S Kobayashi; A Fukamizu; K Murakami; M Ishii
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

6.  Upstream regions of the c-jun promoter regulate phorbol ester-induced transcription in U937 leukemic cells.

Authors:  T Unlap; C C Franklin; F Wagner; A S Kraft
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

7.  The core promoter region of the tumor necrosis factor alpha gene confers phorbol ester responsiveness to upstream transcriptional activators.

Authors:  D C Leitman; E R Mackow; T Williams; J D Baxter; B L West
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

8.  Alteration of a cyclic AMP-dependent protein kinase phosphorylation site in the c-Fos protein augments its transforming potential.

Authors:  I Tratner; R Ofir; I M Verma
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

9.  Multiple pathways for Steel regulation suggested by genomic and sequence analysis of the murine Steel gene.

Authors:  M A Bedell; N G Copeland; N A Jenkins
Journal:  Genetics       Date:  1996-03       Impact factor: 4.562

10.  Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells.

Authors:  J Kikuchi; I Kinoshita; Y Shimizu; S Oizumi; M Nishimura; M J Birrer; H Dosaka-Akita
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.